[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR052887A1 - Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa - Google Patents

Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa

Info

Publication number
AR052887A1
AR052887A1 ARP060100240A ARP060100240A AR052887A1 AR 052887 A1 AR052887 A1 AR 052887A1 AR P060100240 A ARP060100240 A AR P060100240A AR P060100240 A ARP060100240 A AR P060100240A AR 052887 A1 AR052887 A1 AR 052887A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
substituted
alkoxy
cycloalkyl
Prior art date
Application number
ARP060100240A
Other languages
English (en)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR052887A1 publication Critical patent/AR052887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas que comprenden a dichos compuestos y métodos para utilizar dichos compuestos para tratar o prevenir enfermedades o trastornos asociados con la actividad anormal o desregulada de la quinasa, particularmente enfermedades o trastornos que comprenden la activacion anormal de las quinasa Ab1, Bcr-Ab1, FGFR3, PDGFRbeta y b-Raf. Reivindicacion 1: Un compuesto de formula (1), en la que: n se selecciona del 0, 1, 2, 3 y 4; Y se selecciona de C, S, S(O) P y P(O); R1 se selecciona de alquilo C1-6, ariloC6-10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, cicloalquiloC3-12-alquiloC0-4, heterocicloalquiloC3-8- alquiloC0-4 y -XNR7R8; en donde cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R1 se encuentra sustituido con 1-3 radicales independientemente seleccionados de halo, alquilo C1-6, alquiloC1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, alquiltio C1-6, alquiltio C1-6 sustituido con halo, -XNR7R8, -XNR7XNR7R8, - XNR7R9, arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8; en donde cualquier sustituyente arilo, heteroarilo, cicloalquilo o heterocicloalquilo en R1 puede estar opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alquilo C1-6 sustituido con hidroxi, alcoxi C1-6 y alcoxi C1-6 sustituido con halo; y en donde cualquier alquilo de R1 puede tener un metileno reemplazado con O; en donde X se selecciona independientemente de un enlace y alquileno C1-6; R7 y R8 seleccionan independientemente de hidrogeno y alquilo C1-6; en donde cualquier metileno de R7 y R8 se puede reemplazar con O; en donde R9 se selecciona de ariloC6- 10-alquiloC0-4, heteroariloC5-10-alquiloC0-4, cicloalquiloC3-12-alquiloC0-4 y heterocicloalquiloC3-8-alquiloC0-4; R2 se selecciona de hidrogeno y alquilo C1-6; R3 se selecciona de hidrogeno y alquilo C1-6; R4 se selecciona de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi c1-6 sustituido con halo, alquiltio C1-6 y alquiltio C1-6 con halo; R5 se selecciona del hidrogeno y alquilo C1-6; y R6 se selecciona de arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12 y heterocicloalquilo C3-8; en donde dicho arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R6 se encuentra opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxi C1-6, alcoxi C1-6 sustituido con halo, alquiltio C1-6, alquiltio C1-6 sustituido con halo, arilo C6-10, heteroarilo C5-10, cicloalquilo C3-12, y heterocicloalquilo C3-8; en donde los sustituyentes arilo, heteroarilo, cicloalquilo o heterocicloalquilo en R6 pueden estar opcionalmente sustituidos con 1 a 3 radicales independientemente seleccionados de hidroxi, halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alquilo C1-6 sustituido con hidroxi, alcoxi C1-6 y alcoxi C1-6 sustituido con halo; y las sales, hidratos, solvatos, isomeros y profármacos farmacéuticamente aceptables de dichos compuestos.
ARP060100240A 2005-01-26 2006-01-23 Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa AR052887A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64760605P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
AR052887A1 true AR052887A1 (es) 2007-04-11

Family

ID=36740973

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100240A AR052887A1 (es) 2005-01-26 2006-01-23 Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa

Country Status (15)

Country Link
US (1) US20090105250A1 (es)
EP (1) EP1841431A4 (es)
JP (1) JP2008528585A (es)
KR (1) KR100919905B1 (es)
CN (1) CN101106990B (es)
AR (1) AR052887A1 (es)
AU (1) AU2006209183B2 (es)
BR (1) BRPI0607307A2 (es)
CA (1) CA2593803A1 (es)
GT (1) GT200600028A (es)
MX (1) MX2007008973A (es)
PE (1) PE20060877A1 (es)
RU (1) RU2368602C2 (es)
TW (1) TW200637547A (es)
WO (1) WO2006081172A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
EP1904065A2 (en) * 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
EP1986645B1 (en) 2006-01-27 2012-01-04 Array Biopharma, Inc. Glucokinase activators
CA2662580C (en) * 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
MX2009004786A (es) 2006-10-31 2009-06-05 Schering Corp Derivados de anilinopiperazina y sus metodos de uso.
PE20080928A1 (es) 2006-10-31 2008-08-15 Schering Corp Derivados de anilinopiperazina como inhibidores de proteina quinasa
EP2265608A2 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
EP2265609B1 (en) * 2008-02-29 2012-09-05 Array Biopharma, Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
EP2519517B1 (en) * 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2576566B1 (en) 2010-05-28 2015-10-28 Merck Sharp & Dohme B.V. Thieno(2,3b)pyrazine compounds as b-raf inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
RU2011122942A (ru) * 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
AU2012333092B2 (en) * 2011-08-31 2016-04-21 Novartis Ag Synergistic combinations of PI3K- and MEK-inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
RU2495430C1 (ru) * 2012-03-29 2013-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки эффективности терапии хронического миелолейкоза
TW201350479A (zh) 2012-04-26 2013-12-16 Ono Pharmaceutical Co Ｔｒｋ阻害化合物
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
RU2495427C1 (ru) * 2012-07-04 2013-10-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования ответа на химиотерапию при хроническом лимфолейкозе
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
KR20150118148A (ko) 2013-02-19 2015-10-21 오노 야꾸힝 고교 가부시키가이샤 Trk 저해 화합물
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
AU2015335788B2 (en) * 2014-10-22 2020-07-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
EP3423451B1 (en) 2016-03-01 2022-08-17 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
US11174250B2 (en) 2016-03-01 2021-11-16 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
US11345676B2 (en) 2017-03-27 2022-05-31 Pharmakea, Inc. Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
EP3781206A2 (en) 2018-04-20 2021-02-24 iOmx Therapeutics AG A 5-thiazolecarboxamide kinase inhibitor and uses thereof
MX2020011960A (es) * 2018-05-09 2021-01-15 Lg Chemical Ltd Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa.
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
EP3643713A1 (en) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071440A2 (en) * 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
WO2006081172A3 (en) 2006-09-14
MX2007008973A (es) 2007-09-18
CN101106990A (zh) 2008-01-16
US20090105250A1 (en) 2009-04-23
JP2008528585A (ja) 2008-07-31
CN101106990B (zh) 2010-12-08
GT200600028A (es) 2006-10-18
AU2006209183B2 (en) 2009-11-19
TW200637547A (en) 2006-11-01
RU2368602C2 (ru) 2009-09-27
CA2593803A1 (en) 2006-08-03
BRPI0607307A2 (pt) 2009-08-25
RU2007132262A (ru) 2009-03-10
KR100919905B1 (ko) 2009-10-06
EP1841431A4 (en) 2009-12-09
WO2006081172A2 (en) 2006-08-03
PE20060877A1 (es) 2006-10-16
AU2006209183A1 (en) 2006-08-03
EP1841431A2 (en) 2007-10-10
KR20070095978A (ko) 2007-10-01

Similar Documents

Publication Publication Date Title
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
NO20075059L (no) Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20084872L (no) 2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CR10915A (es) Compuestos y metodos de uso de inhibidor phosphoinositide 3-kinase
RU2012109233A (ru) Соединения как модуляторы тирозинкиназы
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20084845L (no) 2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
AR072227A1 (es) Derivados de triazinona sustituidos
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander

Legal Events

Date Code Title Description
FA Abandonment or withdrawal